EP1309718A4 - Neutrokine-alpha et variant d'epissage de neutrokine-alpha - Google Patents

Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Info

Publication number
EP1309718A4
EP1309718A4 EP01967981A EP01967981A EP1309718A4 EP 1309718 A4 EP1309718 A4 EP 1309718A4 EP 01967981 A EP01967981 A EP 01967981A EP 01967981 A EP01967981 A EP 01967981A EP 1309718 A4 EP1309718 A4 EP 1309718A4
Authority
EP
European Patent Office
Prior art keywords
neutrokine
alpha
splice variant
variant
alpha splice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01967981A
Other languages
German (de)
English (en)
Other versions
EP1309718A2 (fr
Inventor
Guo-Liang Yu
Reinhard Ebner
Jian Ni
Craig A Rosen
Stephen Ullrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1309718A2 publication Critical patent/EP1309718A2/fr
Publication of EP1309718A4 publication Critical patent/EP1309718A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
EP01967981A 2000-08-15 2001-08-15 Neutrokine-alpha et variant d'epissage de neutrokine-alpha Withdrawn EP1309718A4 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US22562800P 2000-08-15 2000-08-15
US225628P 2000-08-15
US22700800P 2000-08-23 2000-08-23
US227008P 2000-08-23
US23433800P 2000-09-22 2000-09-22
US234338P 2000-09-22
US24080600P 2000-10-17 2000-10-17
US240806P 2000-10-17
US25002000P 2000-11-30 2000-11-30
US250020P 2000-11-30
US27624801P 2001-03-16 2001-03-16
US276248P 2001-03-16
US29349901P 2001-05-25 2001-05-25
US293499P 2001-05-25
US29612201P 2001-06-07 2001-06-07
US296122P 2001-06-07
US30480901P 2001-07-13 2001-07-13
US304809P 2001-07-13
PCT/US2001/025549 WO2002018620A2 (fr) 2000-08-15 2001-08-15 Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Publications (2)

Publication Number Publication Date
EP1309718A2 EP1309718A2 (fr) 2003-05-14
EP1309718A4 true EP1309718A4 (fr) 2004-08-25

Family

ID=27578713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01967981A Withdrawn EP1309718A4 (fr) 2000-08-15 2001-08-15 Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Country Status (4)

Country Link
EP (1) EP1309718A4 (fr)
AU (1) AU2001288260A1 (fr)
CA (1) CA2419661A1 (fr)
WO (1) WO2002018620A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
EP2974736A1 (fr) 1999-01-25 2016-01-20 Biogen MA Inc. Baff, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules b
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
MXPA02001665A (es) 1999-08-17 2003-07-14 Biogen Inc Receptor de baff (bcma) como agente inmunorregulador.
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP2281843B1 (fr) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte B (BLyS)
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2476675A1 (fr) * 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha
WO2004081043A2 (fr) * 2003-01-06 2004-09-23 Xencor, Inc. Variants de baff et leurs methodes d'utilisation
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
JP5524441B2 (ja) 2003-03-28 2014-06-18 バイオジェン・アイデック・エムエイ・インコーポレイテッド 短縮されたｂａｆｆレセプター
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
EP1629001A2 (fr) 2003-06-05 2006-03-01 Genentech, Inc. Antagonistes de blys et leurs utilisations
CA2583900A1 (fr) * 2004-10-13 2006-04-27 The Washington University Utilisation de baff dans le traitement du sepsis
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
WO1999012964A2 (fr) * 1997-09-12 1999-03-18 Biogen, Inc. Kay, nouvelle proteine du systeme immunitaire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2212299A (en) * 1998-01-05 1999-07-26 Genentech Inc. Compositions and methods for the treatment of tumor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
WO1999012964A2 (fr) * 1997-09-12 1999-03-18 Biogen, Inc. Kay, nouvelle proteine du systeme immunitaire

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROT [online] 16 October 2001 (2001-10-16), "Tumor necrosis factor ligand superfamily member 13B", XP002286038, retrieved from UNIPROT Database accession no. Q9Y275 *
DENARDO G L ET AL: "Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts", CLINICAL CANCER RESEARCH 1998 UNITED STATES, vol. 4, no. 10, 1998, pages 2483 - 2490, XP001181898, ISSN: 1078-0432 *
HEPPELER A ET AL: "RECEPTOR TARGETING FOR TUMOR LOCALISATION AND THERAPY WITH RADIOPEPTIDES", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 9, no. 7, 2000, pages 971 - 994, XP000982225, ISSN: 0929-8673 *
KARPUSAS M ET AL: "Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 315, no. 5, 1 February 2002 (2002-02-01), pages 1145 - 1154, XP004470833, ISSN: 0022-2836 *
LIU YINGFANG ET AL: "Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands", CELL, vol. 108, no. 3, 8 February 2002 (2002-02-08), pages 383 - 394, XP002286032, ISSN: 0092-8674 *
MOORE P A ET AL: "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 285, no. 5425, 9 July 1999 (1999-07-09), pages 260 - 263, XP002142252, ISSN: 0036-8075 *
OREN DEENA A ET AL: "Structural basis of BLyS receptor recognition.", NATURE STRUCTURAL BIOLOGY, vol. 9, no. 4, April 2002 (2002-04-01), pages 288 - 292, XP002286033, ISSN: 1072-8368 (ISSN print) *
SCHNEIDER P ET AL: "BAFF, A NOVEL LIGAND OF THE TUMOR NECROSIS FACTOR FAMILY, STIMULATES B CELL GROWTH", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 189, no. 11, 7 June 1999 (1999-06-07), pages 1747 - 1756, XP000915409, ISSN: 0022-1007 *
SHU H-B ET AL: "TALL-1 IS A NOVEL MEMBER OF THE TNF FAMILY THAT IS DOWN-REGULATED BY MITOGENS", JOURNAL OF LEUKOCYTE BIOLOGY, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL, US, vol. 65, no. 5, May 1999 (1999-05-01), pages 680 - 683, XP000939092, ISSN: 0741-5400 *
YU G ET AL: "APRIL AND TALL-I AND RECEPTORS BCMA AND TACI: SYSTEM FOR REGULATING HUMORAL IMMUNITY", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP,, GB, vol. 1, no. 3, September 2000 (2000-09-01), pages 252 - 256, XP000982268, ISSN: 1529-2908 *

Also Published As

Publication number Publication date
WO2002018620A3 (fr) 2003-03-20
WO2002018620A2 (fr) 2002-03-07
CA2419661A1 (fr) 2002-03-07
EP1309718A2 (fr) 2003-05-14
AU2001288260A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
EP1157110A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EP1309718A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
EG23122A (en) Pyrrolcarboxamides and pyrrolcarbothioamides
AU9667901A (en) Mycoattractants and mycopesticides
HRP20060251B1 (hr) Supstituirani oksazolidinoni i njihova uporaba
EP1507793A4 (fr) Neutrokine-alpha et variant d'epissage de neutrokine-alpha
HK1039399A1 (en) Fuse and fuse support
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
GB0026134D0 (en) Peptides and their use
GB0021497D0 (en) Compounds and their use
GB0028589D0 (en) Optical devices and methods
AU2001291962A1 (en) Angiogenic agents and their uses
IL129907A0 (en) Alternative splice variants
HK1046707A1 (zh) 中性活動(NEUTROKINE)-α與中性活動-α粘接變異
GB0117586D0 (en) "Flooring construction and clip"
GB9929581D0 (en) Comjpositions and their use
AU2001279528A1 (en) Advertising system and game
GB2369132B (en) Anchorage
GB0029496D0 (en) Optipouch and optipad
GB0008876D0 (en) IC2CU and IC2IDU
HU0002418D0 (en) Motor-sprayer with diving-pump and system
AU2001277519A1 (en) Bio-probes and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030305

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/64 B

Ipc: 7C 12N 15/63 B

Ipc: 7C 12N 15/62 B

Ipc: 7C 12N 15/13 B

Ipc: 7C 12N 15/12 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 07K 1/24 B

Ipc: 7C 07K 16/18 B

Ipc: 7C 07K 16/00 B

Ipc: 7A 61K 48/00 B

Ipc: 7A 61K 39/395 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040715

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 51/08 B

Ipc: 7A 61K 38/19 B

Ipc: 7C 07K 14/705 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060113